top of page

Portuguese biotech company sells majority stake to Swiss private equity firm


Portuguese biotech company sells majority stake to Swiss private equity firm - portugal news
Portuguese biotech company sells majority stake to Swiss private equity firm - Portugal Business News

Portugal news - Portuguese biotech company FairJourney Biologics has sold a majority stake to Swiss private equity firm Partners Group, while the founder of FairJourney Biologics, António Parada, will remain a significant shareholder.

 

Portuguese company FairJourney Biologics is a leading antibody discovery Contract Research Organization (CRO) that partners with pharmaceutical and biotech companies for the discovery, production, and characterization of antibody-based therapies. FairJourney is set to benefit from tailwinds in the antibody discovery market, including higher pharmaceutical R&D spending and increased outsourcing.

 

The investment in FairJourney Biologics by Partners Group, alongside a minority reinvestment from GHO Capital, will support FairJourney in accelerating growth. Partners Group, that is one of the largest private equity firms with USD 106 billion invested in private equity, received legal advice from Ropes & Gray, financial and tax advice from PwC, and commercial advice from Larka for this transaction.

 

Founded in 2012 and headquartered in Porto, Portugal, FairJourney provides support to pharmaceutical and biotech companies with cutting edge innovation to develop the next generation of antibody-based therapies. The Portuguese company has worked with over 250 clients across the globe to develop more than 4,000 unique screening libraries for identifying antibodies. FairJourney has already yielded 14 therapies that are currently in active clinical development to treat unmet patient needs across oncology, immunology, and cardiovascular disease.

 

Portuguese biotech company FairJourney Biologics has demonstrated market leading success rates and outcomes driven by the quality of its people and advanced technologies, supported by state-of-the-art operations in Porto and Cambridge.

 

 



Comments

Rated 0 out of 5 stars.
No ratings yet

Add a rating
bottom of page